GleamWall
中文EN

JBIO Jade Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1798749 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-29.9%
TTM EPS YoY44.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-51.4%
ROA-47.4%
ROIC (approx.)-55.4%
Asset turnover—

Leverage & solvency

Liabilities / assets6.4%
Debt / equity0.00x
Current ratio16.03x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$93.12M$53.19M
SG&A expense$20.42M$21.41M
Operating income-$113.54M-$74.60M
Pretax income-$127.35M-$69.57M
Income tax$58,000$55,000
Net income-$127.41M-$69.63M
EBITDA-$113.52M-$74.31M
EPS (basic)-3.19-2.44
EPS (diluted)-3.19-2.44
Weighted avg. shares (diluted)31.36M28.58M
Balance sheet
Cash & equivalents$88.44M$69.39M
Short-term investments$247.72M$0
Current assets$348.82M$69.65M
PP&E, net$170,000$0
Total assets$349.78M$72.80M
Current liabilities$16.54M$12.00M
Total liabilities$17.26M$119.60M
Shareholders' equity$332.52M-$46.80M
Shares outstanding49.32M3.67M
Cash flow statement
Operating cash flow-$94.69M-$71.20M
Capital expenditure$196,000—
Free cash flow-$94.89M—
Investing cash flow-$247.01M$56.03M
Financing cash flow$360.77M$25.43M
Depreciation & amortization$26,000$282,000
Stock-based compensation$20.01M$11.31M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.